Drug Type Small molecule drug |
Synonyms- |
Target |
Action modulators |
Mechanism Cholesterol modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Meibomian Gland Dysfunction | Phase 2 | United States | 05 Sep 2021 |
Phase 2 | 92 | (CBT-006 Lower Concentration) | fjihwsfvuc(scxltuenhd) = sutxwryflj vdrwdwncfe (snrrjijpes, 2.6230) View more | - | 24 Apr 2024 | ||
(CBT-006 Higher Concentration) | fjihwsfvuc(scxltuenhd) = jxfyipegwf vdrwdwncfe (snrrjijpes, 2.6647) View more |





